saroglitazar magnesium

Trials studying saroglitazar magnesium

• phase1Evaluate PK & Safety of Saroglitazar in Subjects With Moderate Hepatic Impairment Due to Cholestatic Liver Diseaserecruitingn=6
• phase1Hepatic Impairment With Cirrhosis Due to Cholestatic Liver Diseaserecruitingn=30
• phase3Study of Saroglitazar Magnesium for PBC Patients With Incomplete Response or Intolerant to UDCA Therapynot yet recruitingn=89
• phase3Long-Term Study to Evaluate the Safety and Efficacy in Participants With Primary Biliary Cholangitis of Saroglitazar Magnesium-V on Clinical Outcomesnot yet recruitingn=386
• phase3Open-Label Extension Study of Saroglitazar Magnesium in Participants With Primary Biliary Cholangitisrecruitingn=150
• phase2Saroglitazar Magnesium 4 mg in the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in Women With PCOS (EVIDENCES VII)terminatedn=60
• phase2Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis With Fibrosiscompletedn=189
• phase2Saroglitazar Magnesium 4 mg for Nonalcoholic Fatty Liver Disease (NAFLD) in People Living With HIV in the USterminatedn=4